Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)
The Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Data were collected retrospectively from 1055 patients undergoing nonablative (n=294) and ablative (n=761) conditioning prior to stem cell transplantation. Median age of the group was 45 and myeloid malignancies constituted the majority of diagnoses (66%). The investigators identified relevant comorbidities and derived a scoring system that predicted for 2-year non-relapse mortality post transplantation, after adjusting for age, disease risk, and conditioning regimen. The HCT-CI is able to classify patients into three risk groups: low risk (non-relapse mortality 14% at 2-years), intermediate risk (non-relapse mortality 21% at 2-years) and high risk (non-relapse mortality 41% at 2-years). The authors caution that other major pretransplant factors, including age and disease stage, should be considered when determining risk for allogeneic transplant.
Mohamed L Sorror, Michael B Maris, Rainer Storb, Frederic Baron, Brenda M Sandmaier, David G Maloney, Barry Storer
Blood 2005 October 15, 106 (8): 2912-9
Charlson et al.
Journal of Chronic Diseases 1987, 40 (5): 373-83
The Hematopoietic cell transplantation - specific comorbidity index (HCT-CI) calculator is created by QxMD.